Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene

Arthritis and Rheumatism

Volumn 40, Issue 9, 1997, Pages 1662-1669

  Le, Christine H ^a,b   Nicolson, A Graham ^a   Morales, Alejandro ^a   Sewell, K Lea ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COLLAGEN; GENE PRODUCT; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SYNOVITIS;

ADENOVIRIDAE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BETA-GALACTOSIDASE; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; KNEE JOINT; NEOPLASM PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 0030808459     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400916     Document Type: Article

References (42)

1. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
2. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127, 1994
3. Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ: Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody: long-term followup of CD+ T cell counts. Arthritis Rheum 37:834-838, 1994
4. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37:992-999, 1994
5. 486 IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum 36:1223-1233, 1993
6. 486 IL-2) in refractory rheumatoid arthritis: a double-blind placebo-controlled trial with open-label extension. Arthritis Rheum 38:1177-1186, 1995
7. Raz E, Watanabe A, Baird SM, Eisenberg RA, Parr TB, Lotz M, Kipps TJ, Carson DA: Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A 90:4523-4527, 1993
8. Gilgenkrantz H, Duboc D, Juillard V, Couton D, Pavirani A, Guillet JG, Briand P, Kahn A: Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther 6:1265-1274, 1995
9. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR, Grossman M, Wilson JM, Johnson LG, Boucher RC: A controlled study of adenoviral vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:823-831, 1995
10. Zhu G, Nicolson AG, Cowley BD, Rosen S, Sukhatme VP: In vivo adenovirus-mediated gene transfer into normal and cystic rat kidneys. Gene Ther 3:298-304, 1996
11. Evans C, Robbins PD: Prospects for treating arthritis by gene therapy. J Rheumatol 21:779-782, 1994
12. Hung GL, Galea-Lauri J, Mueller GM, Georgescu HI, Larkin LA, Suchanek MK, Tindal MH, Robbins PD, Evans CH: Suppression of intraarticular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther 1:64-69, 1994
13. Otani K, Nita I, Macaulay W, Georgescu HI, Robbins PD, Evans CH: Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. J Immunol 156:3558-3562, 1996
14. Chernajovsky Y, Adams G, Podhajcer OL, Mueller GM, Robbins PD, Feldmann M: Inhibition of transfer of collagen-induced arthritis into SCID mice by ex vivo infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor. Gene Ther 2:731-735, 1995
15. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson BL: Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 92:1085-1092, 1993
16. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, Evans CH: Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 39:820-828, 1996
17. Kozarsky KF, Wilson JM: Gene therapy: adenovirus vectors. Curr Opin Genet Dev 3:499-503, 1993
18. Brennan FM, Maini RN, Feldmann M: TNFα: a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:315-324, 1988
19. Deleuran BW, Chu C-Q, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35:1170-1178, 1992
20. Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38:151-160, 1995
21. Felmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A, Field M, Maini RN: Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49:480-486, 1990
22. Lewthwaite J, Blake S, Hardingham T, Foulkes R, Stephens S, Chaplin L, Emtage S, Catterall C, Short S, Nesbitt A, Allen R, Bodmer M, Brown D, Andrew D, Henderson B: Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralizing monoclonal antibodies. Ann Rheum Dis 54:366-374, 1995
23. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89:7375-7379, 1992
24. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 39:797-809, 1996
25. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607, 1993
26. Moreland LW, Margolies GR, Heck LW, Saway PA, Jacobs C, Beck C, Blosch C, Koopman WJ: Soluble tumor necrosis factor receptor: results of a phase 1 dose-escalation study in patients with rheumatoid arthritis (abstract). Arthritis Rheum 37 (suppl 6):R27, 1994
27. Kolls JK, Peppel K, Silva M, Beutler B: Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A 91:215-219, 1994
28. Graham FL, van der Eb AJ: A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467, 1973
29. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Mcd 146:857-868, 1977
30. Trentham DE, Townes AS, Kang AH, David JR: Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest 61:89-96, 1978
31. Caulfield JP, Hein A, Dynesius-Trentham R, Trentham DE: Morphologic demonstration of two stages in the development of type II collagen-induced arthritis. Lab Invest 46:321-343, 1982
32. Ramsey WJ, Mullen CA, Blaese RM: Retrovirus-mediated gene transfer as therapy for adenosine deaminase deficiency. Leukemia 9 (suppl 1):S70, 1995
33. Rosenteld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Paakko PK, Gilardi P, Stratford-Perricaudet L: Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434, 1991
34. Mastrangelo MJ, Berd D, Nathan FE, Lattime EC: Gene therapy for human cancer: an essay for clinicians. Semin Oncol 23:4-21, 1996
35. Voelker R: Gene therapy for HIV. JAMA 275:1533, 1996
36. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B, Karpati G: The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2:107-115, 1995
37. Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B: Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 171:570-575, 1995
38. Peppel K, Crawford D, Beutler B: A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 171:1483-1489, 1991
39. Kolls AK, Lei D, Odom G, Nelson S, Summer WR, Gerber MA, Shellito JE: Use of transient CD4 lymphocyte depletion to prolong transgene expression of El-deleted adenoviral vectors. Hum Gene Ther 7:489-497, 1996
40. DeMatteo RP, Markmann JF, Kozarsky KF, Barker CF, Raper SE: Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther 3:4-12, 1996
41. Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linsley PS, Wilson CB: Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 11:191-197, 1995
42. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 91:6196-6200, 1994